27th Congress of the International Society on Thrombosis and Haemostasis (ISTH)

      Date
      Jul 6, 2019 - Jul 10, 2019
      Location
      Melbourne, Australia
      The International Society on Thrombosis and Haemostasis (ISTH) advances the understanding, prevention, diagnosis and treatment of conditions related to thrombosis and hemostasis. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live. ISTH 2019 is the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place in Melbourne, Australia, July 6-10, 2019. It is the 27th Congress overall and features the 65th annual Scientific and Standardization Committee (SSC) meeting. At ISTH 2019, thousands of the world’s leading experts on thrombosis, hemostasis and vascular biology come together to present the most recent advances, exchange the latest science and discuss the newest clinical applications designed to improve patient care. Through an extensive lineup of educational sessions, poster and oral communications, state-of-the-art lectures, medical industry exhibits and professional networking opportunities, the Congress promotes important scientific discourse and advancement.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.